Nuvation Bio posts Q2 2026 results, expands safusidenib program, reports IBTROZI uptake data

Nuvation Bio reported financial results for the quarter ended June 30, 2026, disclosing $31.7 million in total revenue for the quarter, including $23.2 million in net product revenue for IBTROZI (taletrectinib)¹.

On the commercial side, the company said IBTROZI became the most prescribed ROS1 TKI in both first-line and overall new patient starts in 2026 based on IQVIA claims data from the first five months of the year, with about 85% of new prescriptions this quarter going to TKI-naive patients¹. In regulatory news, the FDA in May 2026 accepted a supplemental New Drug Application for IBTROZI with updated efficacy data in TKI-naive and TKI-pretreated ROS1+ NSCLC patients, targeting a January 4, 2027 action date, based on an additional 10 months of TRUST-I and TRUST-II data showing a median duration of response of 49.7 months and median progression-free survival of 49.6 months in TKI-naive patients¹. Separately, the UK's MHRA validated a Marketing Authorisation Application for taletrectinib submitted by partner Eisai in June 2026¹.

For safusidenib, Nuvation Bio announced updated long-term Phase 2 (J201) data in July 2026 showing, at a median follow-up of 38.8 months, a centrally assessed objective response rate of 51.9% and a 36-month progression-free survival rate of 79.1%, with median PFS not yet reached¹. The company said it is expanding the safusidenib program with two new studies: a pivotal Phase 3 trial outside the U.S. (G307) and a Phase 2 trial in patients who progressed after vorasidenib (G209)¹.

On financing, Nuvation Bio completed a convertible senior notes offering in July 2026 carrying a 0.75% coupon¹, and separately exercised an overallotment option that added to net proceeds during the same month. As of June 30, 2026, the company held cash, cash equivalents, and marketable securities of $661.0 million¹.